In vitro and in vivo anti-angiogenic activities of Panduratin A

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lai, Siew Li ^a   Cheah, Shiau Chuen ^a   Wong, Pooi Fong ^a   Noor, Suzita Mohd ^a   Mustafa, Mohd Rais ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; F ACTIN; GELATINASE A; PANDURATIN A; SEMAXANIB; UNCLASSIFIED DRUG; CHALCONE DERIVATIVE; COLLAGEN; CYTOSTATIC AGENT; CYTOTOXIN; LAMININ; MATRIGEL; PROTEOGLYCAN; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BOESENBERGIA ROTUNDA; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; EMBRYO; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; FETUS; FIBROBLAST; GINGER; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MORPHOGENESIS; MOUSE; NONHUMAN; STRESS FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; ZEBRA FISH; ANIMAL; CELL SURVIVAL; CHEMISTRY; CHEMOTAXIS; CYTOLOGY; CYTOSKELETON; DRUG COMBINATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; SECRETION (PROCESS); ZINGIBERACEAE;

BOESENBERGIA ROTUNDA; DANIO RERIO; MURINAE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CHALCONES; CHEMOTAXIS; COLLAGEN; CYTOSKELETON; CYTOSTATIC AGENTS; CYTOTOXINS; DRUG COMBINATIONS; ENZYME ACTIVATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LAMININ; MATRIX METALLOPROTEINASE 2; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEOGLYCANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZEBRAFISH; ZINGIBERACEAE;

EID: 84861609140     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038103     Document Type: Article

References (42)

1. Munoz-Chapuli R, Quesada AR, Angel Medina M, (2004) Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 61: 2224-2243.
2. Folkman J, (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
3. Samant RS, Shevde LA, (2011) Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2: 1-13.
4. Azam F, Mehta S, Harris AL, (2010) Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 46: 1323-1332.
5. Jeong SJ, Koh W, Lee EO, Lee HJ, Bae H, et al. (2011) Antiangiogenic phytochemicals and medicinal herbs. Phytother Res 25: 1-10.
6. Mojzis J, Varinska L, Mojzisova G, Kostova I, Mirossay L, (2008) Antiangiogenic effects of flavonoids and chalcones. Pharmacol Res 57: 259-265.
7. Ren W, Qiao Z, Wang H, Zhu L, Zhang L, (2003) Flavonoids: promising anticancer agents. Med Res Rev 23: 519-534.
8. Cheah SC, Appleton DR, Lee ST, Lam ML, Hadi AH, et al. (2011) Panduratin A inhibits the growth of A549 cells through induction of apoptosis and inhibition of NF-KappaB translocation. Molecules 16: 2583-2598.
9. Rukayadi Y, Lee K, Han S, Yong D, Hwang JK, (2009) In vitro activities of panduratin A against clinical Staphylococcus strains. Antimicrob Agents Chemother 53: 4529-4532.
10. Sohn JH, Han KL, Lee SH, Hwang JK, (2005) Protective effects of panduratin A against oxidative damage of tert-butylhydroperoxide in human HepG2 cells. Biol Pharm Bull 28: 1083-1086.
11. Yun JM, Kweon MH, Kwon H, Hwang JK, Mukhtar H, (2006) Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145. Carcinogenesis 27: 1454-1464.
12. Yun JM, Kwon H, Hwang JK, (2003) In vitro anti-inflammatory activity of panduratin A isolated from Kaempferia pandurata in RAW264.7 cells. Planta Med 69: 1102-1108.
13. Pang X, Yi T, Yi Z, Cho SG, Qu W, et al. (2009) Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 69: 518-525.
14. Albini A, Benelli R, (2007) The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2: 504-511.
15. Toth M, Fridman R, (2001) Assessment of Gelatinases (MMP-2 and MMP-9) by Gelatin Zymography. Methods Mol Med 57: 163-174.
16. Kok TW, Yue PY, Mak NK, Fan TP, Liu L, et al. (2005) The anti-angiogenic effect of sinomenine. Angiogenesis 8: 3-12.
17. Malinda KM, (2003) In vivo matrigel migration and angiogenesis assays. Methods Mol Med 78: 329-335.
18. Moore GL, Ledford ME, Merydith A, (1981) A micromodification of the Drabkin hemoglobin assay for measuring plasma hemoglobin in the range of 5 to 2000 mg/dl. Biochem Med 26: 167-173.
19. Habeck H, Odenthal J, Walderich B, Maischein H, Schulte-Merker S, (2002) Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. Curr Biol 12: 1405-1412.
20. Zoellner H, Hofler M, Beckmann R, Hufnagl P, Vanyek E, et al. (1996) Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci 109: 2571-2580.
21. Fong TAT, Shawver LK, Sun L, Tang C, App H, et al. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106.
22. Ghosh RN, Lapets O, Haskins JR, (2007) Characteristics and value of directed algorithms in high content screening. Methods Mol Biol 356: 63-81.
23. Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Angeletti R, Fiser A, et al. (2006) Insights into the mechanism of microtubule stabilization by taxol. Ejc Supplements 4: 195-195.
24. Lee JG, Kay EP, (2006) FGF-2-induced wound healing in corneal endothelial cells requires Cdc42 activation and Rho inactivation through the phosphatidylinositol 3-kinase pathway. Invest Ophthalmol Vis Sci 47: 1376-1386.
25. Rodriguez LG, Wu X, Guan JL, (2005) Wound-healing assay. Methods Mol Biol 294: 23-29.
26. Coomber BL, Gotlieb AI, (1990) In vitro endothelial wound repair. Interaction of cell migration and proliferation. Arteriosclerosis 10: 215-222.
27. Childs S, Chen JN, Garrity DM, Fishman MC, (2002) Patterning of angiogenesis in the zebrafish embryo. Development 129: 973-982.
28. Goodwin AM, (2007) In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 74: 172-183.
29. Kerbel RS, (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
30. Lawley TJ, Kubota Y, (1989) Induction of morphologic differentiation of endothelial cells in culture. J Invest Dermatol 93: 59S-61S.
31. Vucenik I, Passaniti A, Vitolo MI, Tantivejkul K, Eggleton P, et al. (2004) Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 25: 2115-2123.
32. kay Ja, (2006) FGF-2-induced wound healing in corneal endothelial cells requires Cdc42 activation and Rho inactivation through the Phosphatidylinositol 3-Kinase Pathway. Invest Ophthalmol Vis Sci pp. 1376-1386.
33. Coomber BL GA, (1990) In vitro endothelial wound repair. Interaction of cell migration and proliferation. Arteriosclerosis pp. 215-222.
34. Lamalice L, Le Boeuf F, Huot J, (2007) Endothelial cell migration during angiogenesis. Circ Res 100: 782-794.
35. Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, Satterwhite LL, (2006) Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc Res 71: 236-246.
36. Shindo K, Kato M, Kinoshita A, Kobayashi A, Koike Y, (2006) Analysis of antioxidant activities contained in the Boesenbergia pandurata Schult. rhizome. Biosci. Biotechnol. Biochem 70: 2281-2284.
37. Foda HD, Zucker S, (2001) Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 6: 478-482.
38. Imai K, Ohuchi E, Aoki T, Nomura H, Fujii Y, et al. (1996) Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 56: 2707-2710.
39. Atkinson SJ, Crabbe T, Cowell S, Ward RV, Butler MJ, et al. (1995) Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem 270: 30479-30485.
40. Fang JM, Shing Y, Wiederschain D, Yan L, Butterfield C, et al. (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. P Natl Acad Sci USA 97: 3884-3889.
41. Kargozaran H, Yuan SY, Breslin JW, Watson KD, Gaudreault N, et al. (2007) A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier. Clin Exp Metastasis 24: 495-502.
42. Kidd KR, Weinstein BM, (2003) Fishing for novel angiogenic therapies. Br J Pharmacol 140: 585-594.